viewAmryt Pharma PLC

Amryt Pharma gets marketing approval in Brazil for specialist cholesterol drug Lojuxta

Chief executive, Dr Joe Wiley, said: “We are pleased that ANVISA has recognised the significant unmet medical need of patients in Brazil"

Amryt Pharma PLC -

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it has received marketing approval from the authorities in Brazil for specialist cholesterol drug Lojuxta.

The rare diseases specialist noted that the drug is used to treat homozygous familial hypercholesterolaemia (HoFH), a rare condition where the body finds it difficult to remove bad cholesterol from the blood.

It has been approved by the regulator ANVISA for use alongside a low-fat diet and other lip-lowering drugs.

In a statement, Amryt's chief executive, Dr Joe Wiley, said: “We are pleased that ANVISA has recognised the significant unmet medical need of patients in Brazil suffering from HoFH and have approved marketing authorisation for Lojuxta to treat adults with this condition.

“Today’s news is another milestone in executing our strategy to make Lojuxta available to HoFH patients in need globally.”

Lojuxta is one of two commercial drugs Amryt has on the market. The other is Myalept, which is approved in the US to treat the complications of leptin deficiency.

The group is preparing to seek regulatory sign-off for FILSUVEZ, developed for epidermolysis bullosa (EB), a chronic and distressing genetic skin disorder that causes the skin layers and internal body linings to separate.

Quick facts: Amryt Pharma PLC

Price: 213 GBX

Market: AIM
Market Cap: £380.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...


Amryt Pharma raises $40M in private placement from new and existing...

Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) CEO Joe Wiley tells Proactive the group has raised $40M from leading biotech investors in a private placement, with a tranche of the proceeds being used to in-license or invest in rare disease technologies. Wiley says investors include Stonepine...

on 9/12/20

2 min read